Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-label, Dose Escalation Study Investigating Different Doses of SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

Next Previous
X
Search
Trial Profile

A Phase 1b, Open-label, Dose Escalation Study Investigating Different Doses of SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guadecitabine (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Proof of concept
  • Acronyms NIBIT-M4

    • Most Recent Events

    • 19 Apr 2023 Results assessing the 5-year clinical outcome of guadecitabine plus ipilimumab in unresectable melanoma of NIBIT-M4 patients and its correlation with an integrated multi-omic analysis, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 17 Sep 2019 Results (n=19) were published in the Clinical Cancer Research.
    • 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top